An expanded genetic code facilitates antibody chemical conjugation involving the lambda light chain

Akifumi Kato, Kazumasa Ohtake, Yoshitaka Tanaka, Shigeyuki Yokoyama, Kensaku Sakamoto, Yasuhisa Shiraishi

研究成果: ジャーナルへの寄稿学術誌査読

1 被引用数 (Scopus)


Most of the currently approved therapeutic antibodies are of the immunoglobulin gamma (IgG) κ isotype, leaving a vast opportunity for the use of IgGλ in medical treatments. The incorporation of designer amino acids into antibodies enables efficient and precise manufacturing of antibody chemical conjugates. Useful conjugation sites have been explored in the constant domain of the human κ-light chain (LCκ), which is no more than 38% identical to its LCλ counterpart in amino acid sequence. In the present study, we used an expanded genetic code for site-specifically incorporating Nε-(o-azidobenzyloxycarbonyl)-L-lysine (o-Az-Z-Lys) into the antigen-binding fragment (Fab) of an IgGλ, cixutumumab. Ten sites in the LCλ constant domain were found to support efficient chemical conjugation exploiting the bio-orthogonal azido chemistry. Most of the identified positions are located in regions that differ between the two light chain isotypes, thus being specific to the λ isotype. Finally, o-Az-Z-Lys was incorporated into the Fab fragments of cixutumumab and trastuzumab to chemically combine them; the resulting bispecific Fab-dimers showed a strong antagonistic activity against a cancer cell line. The present results expand the utility of the chemical conjugation method to the whole spectrum of humanized antibodies, including the λ isotype.

ジャーナルBiochemical and Biophysical Research Communications
出版ステータス出版済み - 3月 26 2021

!!!All Science Journal Classification (ASJC) codes

  • 生物理学
  • 生化学
  • 分子生物学
  • 細胞生物学


「An expanded genetic code facilitates antibody chemical conjugation involving the lambda light chain」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。